Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Seasonal Allergic Rhinitis
NCT07199257Phase 3Not yet recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telikibart in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Zhixiang Jintai. Primary endpoints: Adverse events at 12 weeks and Change from Baseline in reflective Total Nasal Symptom Scores at 2 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
telikibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07199257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199257.